Klinische Wochenschrift

, Volume 68, Issue 19, pp 935–941 | Cite as

New approaches in the treatment of the dystonias

  • N. Diederich
  • C. G. Goetz
  • C. L. Comella
Review
Received:
Revised:
Accepted:

Summary

At this point the treatment of dystonias remains highly empirical. Secondary dystonias, especially those related to specific drug treatment, have to be ruled out carefully. A few dystonic subgroups respond well to levodopa medication. In the other syndromes, anticholinergics are the usual first choice. In focal conditions botulinum toxin injections seem to be the most effective regimen, although there are only a few long-term studies. Surgical procedures are an ultimate option.

Key words

Dystonia Anticholinergics Botulinum toxin Stereotaxy 

Abbreviations

PET

positron emission tomography

CT

computer tomography

MRI

magnetic resonance imaging

HIV

human immundeficiency virus

EMG

electromyography

AIDS

acquired immunodeficiency virus

PTH

parathyroid hormone

DMD

dystonia musculorum deformans

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andrew J, Fowler CJ, Harrison H JG (1983) Stereotactic thalamotomy in 55 cases of dystonia. Brain 106:981–1000Google Scholar
  2. 2.
    Bertrand C (1981) Stereotactic and peripheral surgery for the control of movement disorders. In: Barbeau A (ed) Disorders of movements. Lippincott, Philadelphia Toronto, pp 191–208Google Scholar
  3. 3.
    Bertrand CM, Molina-Negro P (1988) Selective peripheral denervation in 111 cases of spasmodic torticollis: rationale and results. In: Fahn S et al. (eds) Advances in neurology, vol 50, Dystonia 2, pp 637–643Google Scholar
  4. 4.
    Breakefield XO, Bressman S (1987) Molecular genetics of movement disorders. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 33–60Google Scholar
  5. 5.
    Bressman SB, De Leon D, Brin MF, Risch N, Burke RE, Grune PE, Shale H, Fahn S (1989) Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 26:612–620Google Scholar
  6. 6.
    Brin MF, Fahn S, Moskowith CB, Blitzer A, Friedman A, Shale HM, Green PE, List T, Lovelace RE (1986) Injections of botulinum toxin for the treatment of focal dystonia. Neurology 36:120Google Scholar
  7. 7.
    Burke RE, Fahn S, Marsden CD (1986) Torsion dystonia: A double blind prospective trial of high-dosage trihexyphenidyl. Neurology 36:160–164Google Scholar
  8. 8.
    Calne DB, Lang AE (1988) Secondary dystonia. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 9–33Google Scholar
  9. 9.
    Claus D (1989) Behandlung von Dystonien und fazialen Dyskinesien. Nervenheilkunde 8:288–292Google Scholar
  10. 10.
    Cohen DA, Savino PS, Stern MB, Hurtig HI (1986) Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin Neuropharmacol 9/5:415–429Google Scholar
  11. 11.
    Cohen LG, Hallett M, Geller BD, Hochberg F (1989) Treatment of focal dystonias of the hand with botulinum toxin injections. J Neurology, Neurosurg Psychiatry 52:355–363Google Scholar
  12. 12.
    Comella CL, Tanner CM, De Foor-Hill L, Smith CS (May 1990) Dysphagia after botulinum toxin treatment of spasmodic torticollis. Abstract American Academy of NeurologyGoogle Scholar
  13. 13.
    Cooper IS (1969) Involuntary movement disorders. Harper Row, New YorkGoogle Scholar
  14. 14.
    Cooper IS (1976) 20-year follow-up study of the neurosurgical treatment of dystonia musculorum deformans. In: Eldridge R, Fahn S (eds) Advances in neurology, vol 14, pp 423–447Google Scholar
  15. 15.
    Deanno T (1986) Dopa-sensitive progressive dystonia of childhood with fluctuations of symptoms: Segawa's syndrome and possible variants. Neuropediatrics 17:81–85Google Scholar
  16. 16.
    Dressler D, Benecke R, Conrad B (1989) Botulinum-Toxin in der Therapie kraniozervikaler Dystonien. Nervenarzt 60:386–393Google Scholar
  17. 17.
    Deuschl G (1989) Der idiopathische Torticollis spasmodicus: eine fokale Dystonie. Nervenarzt 60:377–385Google Scholar
  18. 18.
    Eldridge R (1970) The torsion dystonias; literature review and genetical and clinical studies. Neurology (Minn) 20, 11(2):1–78Google Scholar
  19. 19.
    Engstrom PF, Arnoult JB, Mazow ML, Prager TC, Wilkins RB, Byrd WA, Hofman RJ (1987) Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 94:971–975Google Scholar
  20. 20.
    Fahn S (1983) High dosage anticholinergic therapy in dystonia. Neurology (Cleveland) 33:1255–1261Google Scholar
  21. 21.
    Fahn S (1984) The varied clinical expression of dystonia. Neurologic Clinics vol 2, 3, pp 541–554Google Scholar
  22. 22.
    Fahn S, Marsden CD (1987) The treatment of dystonia. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 359–382Google Scholar
  23. 23.
    Fahn S, Marsden CD, Calne DB (1987) Classification and investigation of dystonia. In: Marsden CD, Fahn S (eds) Movement Disorders 2. Butterworths, London, pp 332–358Google Scholar
  24. 24.
    Fahn S (1988) Concept and Classification of dystonia. In: Fahn S et al. (eds) Advances in neurology, vol 50, Dystonia 2, pp 1–8Google Scholar
  25. 25.
    Fink JK, Barton N, Cohen W, Lovenberg W, Burns RS, Hallett M (1988) Dystonia with marked diurnal variation associated with biopterin deficiency. Neurology 38:707–711Google Scholar
  26. 26.
    Freckmann N, Hagenah R, Hermann HD, Müller D (1986) Bilateral microsurgicallysis of the spinal accessory nerve roots for treatment of spasmodic torticollis. Act Neurochir (Wien) 83:47–53Google Scholar
  27. 27.
    Gauthier S, Perot P, Bertrand G (1988) Role of surgical anterior rhizotomies in the management of spasmodic torticollis. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 633–635Google Scholar
  28. 28.
    Gelb DJ, Lowenstein DH, Aminoff MJ (1989) Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology 39:80–84Google Scholar
  29. 29.
    Goetz CG, Penn RD, Tanner CM (1988) Efficacy of cervical cord stimulation in dystonia. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 645–649Google Scholar
  30. 30.
    Greene P, Shale H, Fahn S (1988) Experience with high dosages of anticholinergics and other drugs in the treatment of torsion dystonia. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 547–556Google Scholar
  31. 31.
    Hornykiewicz O, Kish SJ, Becker LE, Farley I, Shannak K (1986) Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med 316 (6):347–353Google Scholar
  32. 32.
    Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37 (4):616–623Google Scholar
  33. 33.
    Jankovic J (1988) Blepharospasm and oromoandibular-laryngeal-cervical Dystonia: a controlled trial of botulinum a toxin therapy. In: Fahn S et al. (eds) Advances in neurology, vol 50, Dystonia 2, pp 583–591Google Scholar
  34. 34.
    Jankovic J, Nutt JG (1988) Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. In: Jankovic J, Tolosa E (eds) Facial dyskinesias. Adv Neurol 49:117–123Google Scholar
  35. 35.
    Jankovic J, Orman J (1988) Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesias. Neurology 38:391–394Google Scholar
  36. 36.
    Jankovic J, Van der Linden C (1988) Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry 51:1512–1519Google Scholar
  37. 37.
    Jankovic J, Schwartz K (1990) Botulinum toxin injections for cervical dystonia. Neurology 40:277–280Google Scholar
  38. 38.
    Kang UJ, Burke RE, Fahn S (1986) Natural history and treatment of tardive dystonia. Mov Disord 1, 3, pp 193–208Google Scholar
  39. 39.
    Kartzinel R, Chase N (1977) Pharmacology of dystonia. In: Klawans HL (eds) Clinical neuropharmacology, vol 2, Raven Press, New York, pp 43–53Google Scholar
  40. 40.
    Katchen M, Duvoisin RC (1986) Parkinsonism following dystonia in three patients. Mov Disord 1/2:151–157Google Scholar
  41. 41.
    Kidron D, Melamed E (1987) Forms of dystonia in patients with Parkinson's disease. Neurology 37/6:1009–1011Google Scholar
  42. 42.
    Klawans HL, Paleologos N (1986) Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists. Clin Neuropharm 9/3:298–302Google Scholar
  43. 43.
    Kramer PL, De Leon D, Ozelius L, Risch N, Bressman SB, Brin MF, Schuback DE, Burke RE, Kwiatkowski DJ, Shale H, Gusella JF, Breakefield XO, Fahn S (1990) Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. Ann Neurol 27:114–120Google Scholar
  44. 44.
    Lang AE (1985) Dopamine agonists in the treatment of dystonia. Clin Neuropharm 8/1:38–57Google Scholar
  45. 45.
    Lang AE (1986) High dose anticholinergic therapy in adult dystonia. Can J Neurol Sci 13:42–46Google Scholar
  46. 46.
    Lange DL, Brin MF, Fahn S, Lovelace RE (1988) Distant effects of locally injected botulinum toxin: incidence and course. In: Fahn S et al. (eds) Advances in neruology vol 50, Dystonia 2, pp 609–613Google Scholar
  47. 47.
    Lees AJ, Kleedorfer B, Foster H (1989) Treatment of writer's dystonia. Lancet 30:1525Google Scholar
  48. 48.
    Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M (1988) Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 38:1220–1225Google Scholar
  49. 49.
    Marsden CD, Harrisan MJG (1974) Idiopathic torsion dystonia. Brain 97:783–810Google Scholar
  50. 50.
    Marsden CD (1976) The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, or axial dystonia). In: Eldridge R, Fahn S (eds) Advances in neurology, vol 14, Raven Press, New York, pp 259–279Google Scholar
  51. 51.
    Marsden CD (1981) Treatment of torsion dystonia. In: Barbeau A (ed) Disorders of movements. Lippincott, Philadelphia Toronto, pp 81–104Google Scholar
  52. 52.
    Mundinger F, Riechert T, Disselhof J (1972) Long-term results of stereotactic treatment of spasmodic torticollis. Confin neurol 34:41–46Google Scholar
  53. 53.
    Nygaard TG, Duvoisin RC (1986) Hereditary dystonia-parkinsonism syndrome of juvenile onset. Neurology 36:1424–1428Google Scholar
  54. 54.
    Oppenheim H (1911) über eine eigenartige Krankheit des kindlichen und jugendlichen Alters (Dystonia tardiva progressiva, dystonia musculorum deformans). Neurol Zentralbl 30:1090–1107Google Scholar
  55. 55.
    Perlmutter JS, Raichle ME (1984) Pure hemidystonia with basal ganglion abnormalities on positron emission tomography. Ann Neurol 15:228–233Google Scholar
  56. 56.
    Poewe W, Kleedorfer B (1989) Therapie des essentiellen Blepharospasmus und hemifacialen Spasmus mit lokalen Injektionen von Botulinum Toxin Typ A: Erfahrungen an 50 Patienten. Akt Neurol 78–82Google Scholar
  57. 57.
    Przuntek H, Baumgarten F, Hohlhepp W, Koch M (1987) Extrapyramidale Erkrankungen (au\er Parkinson-Syndrom). In: Flügel KA (Hrsg) Neurologische und psychiatrische Therapie, 2. Auflage, perimed, Erlangen, s 395–428Google Scholar
  58. 58.
    Russegger L, Grunnert V (1989) Klinische und therapeutische Aspekte des essentiellen Blepharospasmus. Nervenarzt 60:401–406Google Scholar
  59. 59.
    Quinn N, Hallett M (1989) Dose standardisation of botulinum toxin, Lancet: 964Google Scholar
  60. 60.
    Schoenberg BS (1987) Epidemiology of movement disorders. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 17–32Google Scholar
  61. 61.
    Schott GD (1985) The relationship of peripheral trauma and pain to dystonia. J Neurol Neurosurg Psychiatry 48:698–701Google Scholar
  62. 62.
    Segawa M, Hosaka A, Miyagawa F, Nomura Y, Jmai H (1976) Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 14:215–233Google Scholar
  63. 63.
    Shima F, Fukin M, Kitamura K, Kuromatsu C, Okamura T (1988) Diagnosis and surgical treatment of spasmodic torticollis of 11th nerve origin. Neurosurgery 22:358–363Google Scholar
  64. 64.
    Stell R, Thompson PD, Marsden CD (1988) Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 51:920–923Google Scholar
  65. 65.
    Stell R, Thompson PD, Marsden CD (1989) Botulinum toxin in torticollis. J Neurol 39:1403–1404Google Scholar
  66. 66.
    Stahl SM (1986) Neuropharmacology of movement disorders. Comparison of spontaneous and drug-induced movement disorders. In: NS Shah, Donald AG (eds) Movement disorders. Plenum Medical Book, New York, pp 1–38Google Scholar
  67. 67.
    Stoessl AJ, Martin WRW, Clark C, Adam MJ, Amman W, Bergstran JH, Harrap R, Rogers JG, Ruth TJ, Sayre CI, Pate BD, Calne DB (1986) PET studies of cerebral glucose metabolism in idiopathic torticollis. Neurology 36:653–656Google Scholar
  68. 68.
    Sunohara H, Mano Y, Ando Kl, Sayoschi E (1985) Idiopathic dystonia-parkinsonism with marked diurnal fluctuation of symptoms. Ann Neurol 17:39–45Google Scholar
  69. 69.
    Tanner CM, Goetz CG, Weiner WJ, Nausieda PA, Wilson R, Klawans HL (1979) The role of cholinergic mechanisms in spasmodic torticolis. Neurology 29:604Google Scholar
  70. 70.
    Tanner CM, Wilson RS, Goetz CG, Shannon KM (1988) The predictive value of acute antimuscarinic drugs for the chronic efficacy of antimuscarinic drugs in adults with focal dystonia. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 557–560Google Scholar
  71. 71.
    Tasker RR, Doorly T, Yamashiro K (1988) Thalamotomy in generalized dystonia. In: Fahn S, Marsden CD, Calne DB (eds) Advances in neurology 50, Raven Press, New York, pp 615–631Google Scholar
  72. 72.
    Tolosa ES, Lai Ch-W (1979) Meige disease: striatal dopaminergic preponderance. Neurology 29:1126–1130Google Scholar
  73. 73.
    Trauma and dystonia (1989) Lancet I:759–760Google Scholar
  74. 74.
    Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 11:245–246Google Scholar
  75. 75.
    Tsui JKC, Eisen A, Calne DB (1988) Botulinum toxin in spasmodic torticollis. In: Fahn S et al. (eds) Advances in neurology vol 50, Dystonia 2, pp 593–597Google Scholar
  76. 76.
    Waltz J (1981) Surgical approach to dystonia. In: Marsden CD, Fahn S (eds) Movement disorders, Raven Press, New York, pp 300–307Google Scholar
  77. 77.
    Zeman W, Dyken P (1968) Dystonia musculorum deformans. In: Winken PJ, Bruyn GW, Klawans HL (eds) Handbook of clinical neurology, vol 6. Diseases of the basal ganglia. North Holland, Amsterdam, pp 517–543Google Scholar
  78. 78.
    Zilber N, Korczyn AD, Kahana E et al. (1984) Inheritance of idiopathic torsion dystonia among Jews, J Med Genetics 21:13–20Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • N. Diederich
    • 1
  • C. G. Goetz
    • 2
  • C. L. Comella
    • 2
  1. 1.Klinik für Neurochirurgie der UniversitÄt KölnDeutschland
  2. 2.Neurological DepartmentRush Presbyterian St. Luke's Medical CenterChicago

Personalised recommendations